LoginRegister

    USFDA gives nod to Glenmark's contraceptive drug

    Written by Ruby Khatun Khatun   |  
    USFDA gives nod to Glenmarks contraceptive drug

    New Delhi: Glenmark Pharmaceuticals has received final approval from the US health regulator for a generic version of Minastrin 24 tablets used for prevention of pregnancy.


    "Glenmark Pharmaceuticals USA has been granted final approval by the US Food and Drug Administration (USFDA) for Norethindrone Acetate and Ethinyl Estradiol tablets USP and Ferrous Fumarate tablets, 1 mg/20 mcg, the generic version of Minastrin 24 Fe tablets," the company said in a BSE filing.


    The approved product is a generic version of Allergan Pharmaceuticals International Ltd's Minastrin 24 Fe tablets.


    For the 12 months to October 2017, the Minastrin 24 Fe tablets market achieved annual sales of approximately USD 337 million, Glenmark said, citing IQVIA sales data.


    The company's current portfolio consists of 130 products authorised for distribution in the US marketplace and 58 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA.

    abbreviated new drug applicationsAllerganaprrovalcontraceptive drugethinyl estradiolFerrous Fumarategeneric versionGlenmarkGlenmark PharmaGlenmark PharmaceuticalsMinastrin 24 Fe tabletsMinastrin 24 tabletsnorethindrone acetatepregnancyUS Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X